Head and neck cancer is a medical term used to describe different malignant tumors that develop in or around the nose, throat, sinuses, larynx, and mouth. Most head and neck cancers are squamous cell carcinomas. Head and neck cancer is highly curable if detected early, however, the treatment depends on a number of factors.
Growing burden of head and neck cancer, rise in focus on disease diagnosis, increase in cigarette smoking, alcohol consumption, and high use of tobacco, high demand for safe and effective drugs or treatment, and increasing research and development are major factors expected to augment the growth of the global head and neck cancer drugsmarket.
For instance, in February 2022, University of Cincinnati researchers launched a new clinical trial to examine if the combination of a localized radiation treatment and immunotherapy can be a better treatment for patients with recurrent head and neck cancer.
Moreover, in February 2021, the U.S. FDA granted breakthrough therapy designation to Tipifarnib developed by Kura Oncology, Inc., for the treatment of patients with head and neck squamous cell carcinoma (HNSCC). This is a potent, selective, and orally administered drug.
- This report provides in-depth analysis of the global head and neck cancer drugsmarket, and provides market size (USD Mn) and compound annual growth rate (CAGR %) for the forecast period 2025-2032, considering 2024 as the base year.
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
- It profiles key players in the global head and neck cancer drugsmarket based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
- Key companies covered as a part of this study include Merck & Co., Inc., Eli Lilly and Company, Bristol-Myers Squibb Company, Astrazeneca Plc., Fresenius Medical Care AG & CO. KGAA, and F. Hoffmann-la Roche Ltd. (Genentech, Inc.,), among others.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
- The global head and neck cancer drugsmarket report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global head and neck cancer drugsmarket.
-
- Chemotherapy
- Immunotherapy
- Targeted Therapy
-
- Hospital Pharmacies
- Drug Stores & Retail Pharmacies
- Online Stores
-
- North America
- Europe
- U.K.
- Germany
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Latin America
- Brazil
- Mexico
- Rest of Latin America
- Middle East
- GCC
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
-
- Merck & Co., Inc.
- Eli Lilly and Company
- Bristol-Myers Squibb Company
- Astrazeneca Plc.
- Fresenius Medical Care AG & CO. KGAA
- F.Hoffmann-la Roche Ltd. (Genentech, Inc.)
